Humacyte, Inc. (HUMA)
| Previous close | 4.7000 |
| Open | 4.7400 |
| Bid | 4.8800 x 400 |
| Ask | 5.0000 x 200 |
| Day's range | 4.7380 - 5.0899 |
| 52-week range | 1.9600 - 5.0899 |
| Volume | |
| Avg. volume | 1,410,893 |
| Market cap | 588.275M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0700 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.67 |
GlobeNewswireHumacyte to Participate at Upcoming Investor Conferences in May
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May. H.C. Wainwright BioConnect Investor Conferenc
- GuruFocus.com
Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances
Key Financial and Operational Highlights from the First Quarter
- GlobeNewswire
Humacyte First Quarter 2024 Financial Results and Business Update
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at com
